Elysium Health is an organization that researches, creates, and distributes supplements intended to help people live healthier lives for longer than they would without consuming the products Elysium creates. Elysium Health was founded by two businessmen and a medical researcher.
The basics of Basis, Elysium Health’s flagship supplement
In 2015, the year after Elysium Health was founded, the organization released Basis. Earlier this year, in the early months of 2017, Elysium Health financed the clinical trial of Basis, proving that it does what it states it does – increase the blood serum concentration of NAD+, the initialism of nicotinamide adenine dinucleotide.
Basis is intended to be taken once per day. Two capsules should be taken every morning, as Elysium Health recommends its consumers do, with or without food, meaning it does not typically cause nausea in its consumers. While Basis contains six ingredients, only two of them are active and intended to promote and maintain the cellular health of its consumers: nicotinamide riboside and pterostilbene.
Nicotinamide riboside is intended, once it’s digested, to create stores of nicotinamide adenine dinucleotide in its consumers. Pterostilbene lubricates NAD+ and helps it work as it’s intended.
How can consumers be confident that Basis actually works?
It’s an indisputable fact that many supplements do not have the tried-and-true information backing its manufacturers’ claims. Supplements aren’t regulated by the United States Food and Drug Administration, unlike medications, which are, at least if they’re produced and sold within the United States of America.
Earlier this year, in 2017, Elysium Health funded the clinical trial of the two main ingredients in Basis: nicotinamide riboside and pterostilbene.
The clinical trial involved 120 people and was double-blind, meaning neither doctors nor patients knew whether they were actually taking the real supplement or a placebo, randomized, meaning nobody knew which people actually were taking Basis’ two main ingredients, and standardized. These three characteristics are the three central hallmarks of clinical trials in the United States – and the rest of the world, for that matter.
After taking Basis’ two central components for a total of four straight weeks at least once per day, the serum concentration of nicotinamide adenine dinucleotide – the substance that nicotinamide riboside is designed to yield once consumed – rose an average of 40% in people that took 250 milligrams of nicotinamide riboside and 50 milligrams of pterostilbene. People that took twice this amount – which happens to be the recommended dosage of Basis – were found to have increased 90%. Those that didn’t take anything didn’t see their NAD+ levels rise in any capacity.